Total and individual symptom scores after 12 weeks of treatment
Parameter | Treatment | Mean | Difference relative to placebo | ||
% | 95% CI | p-value | |||
Sleep disturbance | Formoterol 4.5 µg | 1.64 | 99.32 | 93.39–105.62 | 0.8271 |
Formoterol 9 µg | 1.66 | 100.60 | 94.51–107.08 | 0.8506 | |
Formoterol 18 µg | 1.56 | 94.29 | 88.71–100.22 | 0.0588 | |
Placebo | 1.65 | ||||
Breathlessness | Formoterol 4.5 µg | 2.29 | 96.75 | 91.13–102.72 | 0.2784 |
Formoterol 9 µg | 2.19 | 92.65 | 87.20–98.44 | 0.0136 | |
Formoterol 18 µg | 2.15 | 90.76 | 85.53–96.31 | 0.0014 | |
Placebo | 2.37 | ||||
Cough | Formoterol 4.5 µg | 2.01 | 96.64 | 90.75–102.91 | 0.2864 |
Formoterol 9 µg | 2.03 | 97.78 | 91.73–104.23 | 0.4905 | |
Formoterol 18 µg | 2.03 | 97.57 | 91.67–103.85 | 0.4391 | |
Placebo | 2.08 | ||||
Chest tightness | Formoterol 4.5 µg | 1.81 | 96.56 | 90.59–102.93 | 0.2822 |
Formoterol 9 µg | 1.66 | 88.98 | 83.40–94.93 | 0.0004 | |
Formoterol 18 µg | 1.72 | 91.99 | 86.35–98.01 | 0.0099 | |
Placebo | 1.87 | ||||
Total symptom score# | Formoterol 4.5 µg | 4.68 | 94.05 | 86.23–102.58 | 0.1660 |
Formoterol 9 µg | 4.58 | 92.16 | 84.39–100.64 | 0.0691 | |
Formoterol 18 µg | 4.34 | 87.25 | 80.06–95.09 | 0.0019 | |
Placebo | 4.97 |
Data are presented as adjusted geometric means unless otherwise stated
CI: confidence interval
#: adjusted geometric means calculated from the multiplicative analysis of the average total symptom score